BioStem Technologies Reports First Quarter 2026 Financial Results
BioStem Technologies reported Q1 2026 revenue of $6.1 million, a 62% decline year-over-year and a 40% drop from the prior quarter, driven by a mix shift toward lower-margin products. The company posted a GAAP net loss of $8.8 million ($0.52 per share) compared to $3.9 million in net income a year ago, with gross margins compressing from 95% to 61%.
Key figures
- Revenue
- 6135530
- Guidance
- FY26 revenue $25 million to $29 million
- Revenue Yoy
- -61.5%
- Gross margin
- 61%
- Gross profit
- 3759491
- Operating expenses
- 12644043
- Cash and equivalents
- 13703351
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.